Business Wire

PA-PCI-PHARMA-SERVICES

27.7.2022 10:02:09 CEST | Business Wire | Press release

Share
PCI Pharma Services Announces Multi-Million Dollar Expansion to UK Manufacturing Facility to Meet Growing Demand for Global High Potent Manufacturing Services Supporting Oncology Treatments

PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced a significant expansion of its world-class facility in Tredegar, Wales, UK, designed to help keep pace with the market growth of powerful, targeted oncology therapies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220727005014/en/

“We’re excited to announce the latest expansion in Tredegar that will address the growing and urgent need for specialty global manufacturing services within the oncology arena,” said Salim Haffar, Chief Executive Officer, PCI Pharma Services. “As the market expands for potent therapies and highly complex, concentrated formulations that can present unique challenges to manufacturing and packaging, we’re proud to be one of the few providers with the global capabilities to manage this specialty at both clinical and importantly, commercial scale.”

The expansion includes two new facilities dedicated to the manufacturing and packaging of solid oral-dose tablets and capsules. A second contained manufacturing building (CMF2), capitalizing on the success of the original CMF1 which opened in 2013, will double large-scale processing capacity including dispensing and fluid bed granulation of high-potency solid-dose products at the commercial scale. In addition, there is a new high-potency, multi-product packaging facility with primary and secondary blistering and bottling suites. The primary and secondary packaging lines provide a fully integrated process, delivering end-to-end services for a global client base.

More than 1,300 medicines and vaccines in clinical trials were indicated for cancer treatment in 2021, compared to 1,100 two years prior. Oncology treatments also accounted for 25% of all medicines approved by the FDA between 2010 and 2019, signaling that oncology will remain a key focus for the industry in the upcoming years.

“The rapid evolution of oncology pipelines has coincided with the continued globalization of clinical development,” said Rebecca Coutts, Ph.D., General Manager, Tredegar, PCI Pharma Services. “This latest investment, along with the existing analytical and formulation capabilities, combines a clinical and c ommercial scale packaging facility to complement the existing clinical and increased commercial scale manufacturing capabilities, placing end-to-end services for these high-potency molecules under one roof to better serve our client’s evolving needs.”

Both facilities will contain state-of-the-art equipment, including a replica of CMF1’s large-scale granulation suite and a down-flow booth with containment screening. Duplicating the original state-of-the-art CMF1 facility will provide both greater capacity and business continuity for clients.

The Tredegar expansion is also expected to create up to 40 new jobs in the first year and add more as the facilities scale up. PCI Tredegar currently employs close to 500 people, almost doubling the number of employees since the opening of CMF1 in 2013. PCI has been operating in Tredegar UK for nearly 40 years and is one of the most significant employers in the local area. For more information on PCI’s high potent development and manufacturing capabilities, please click here .

About PCI Pharma Services

PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release

Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release

Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene

Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release

Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req

From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release

The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye